Pernix Therapeutics Holdings To Report Second Quarter 2011 Financial Results On August 16, 2011
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty
pharmaceutical company primarily focused on the pediatric market, today
announced that it will release its second quarter 2011 financial results
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced that it will release its second quarter 2011 financial results before the U.S. stock market opens on Tuesday, August 16, 2011. The Company has scheduled a conference call on August 16, 2011 at 9:00 am EDT to discuss the financial results and the current launch of Natroba TM (spinosad) topical suspension 0.9%, a prescription treatment for head lice. The conference call will feature remarks by Cooper Collins, Chief Executive Officer, and Tracy Clifford, Chief Financial Officer. To participate in the conference call, please dial (800) 311-6662 (domestic) or (719) 325-2190 (international). Participants can reference the passcode 6349282. Please dial in approximately 5 minutes prior to the call. The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company’s website, www.pernixtx.com. Please allow extra time prior to the call to visit the Company’s website and download any software that may be needed to listen to the webcast. A replay of the conference call will be available through August 23, 2011, at (888) 203-1112 (domestic) or (719) 457-0820 (international). The passcode for the replay is 6349282. An online archive of the webcast will be available on the Company's website for 30 days following the call. About Pernix Therapeutics Holdings, Inc. Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded and generic pharmaceutical products primarily for the pediatric market. The Company manages a portfolio of branded and generic products and Theobromine, a late-stage development product candidate. The Company’s branded products include its family of prescription treatments for cough and cold (Brovex®, Aldex® and Pediatex®) and CEDAX® (ceftibuten), an antibiotic for middle ear infections. Pernix also seeks to expand its portfolio of branded products through collaborations such as the co-promotion agreement with ParaPRO, LLC to market Natroba™, an FDA-approved topical treatment for head lice. The Company promotes its branded products through an established U.S. sales force. Pernix also markets generic products through its wholly-owned subsidiary, Macoven Pharmaceuticals. Founded in 1996, the Company is based in The Woodlands, TX.